Holland Foundation Looks to Expand Vision-Saving Transplants

Why It Matters

Standardizing systemic immunosuppression and dedicated coordination dramatically improves graft survival for patients with severe corneal blindness, addressing a large, underserved population. Scaling the model accelerates access to vision‑saving surgery and stimulates investment in ocular transplant innovation.

Key Takeaways

• Holland Foundation trains surgeons in Cincinnati Protocol for corneal transplants.
• Five centers of excellence opened; goal 10‑12 nationwide.
• $5 million Light After Darkness campaign funds education and expansion.
• New ocular surface transplant coordinator role improves patient management.
• Eye Love Rock N’ Roll fundraiser scheduled April 11 at Howard Theatre.

Pulse Analysis

The prevalence of corneal blindness caused by severe ocular surface disease has long outpaced treatment options, leaving thousands without viable sight restoration. Traditional corneal grafts often failed because surgeons lacked a systematic approach to donor‑recipient matching and long‑term immunosuppression. Dr. Edward J. Holland’s Cincinnati Protocol borrowed rigor from renal, heart and pancreas transplantation, introducing pre‑operative testing, systemic immunosuppressive regimens, and a dedicated transplant coordinator. Early clinical data show markedly higher graft survival and visual recovery, positioning the protocol as a breakthrough in stem‑cell‑based ocular surface transplantation.

The Holland Foundation is translating that clinical success into a national network. Five “centers of excellence” are already operating—from the Cincinnati Eye Institute to sites in California, Virginia and Massachusetts—with a tenth‑to‑twelfth center slated for the Midwest. Through a robust fellowship program, the foundation has trained dozens of corneal surgeons to adopt the protocol, while a newly created ocular surface transplant coordinator ensures consistent patient monitoring and medication management. The Light After Darkness five‑year campaign aims to raise $5 million, funding additional centers, education initiatives, and the high‑cost immunosuppressive drugs that underpin the technique.

From an industry perspective, the foundation’s model demonstrates how cross‑disciplinary transplant practices can revitalize a stagnant ophthalmic segment. By proving economic viability—through fundraising events like the Eye Love Rock N’ Roll concert and corporate sponsorships—the program attracts capital that can offset the high expense of systemic immunosuppression. Wider adoption could spur device manufacturers to develop targeted drug‑delivery systems and stimulate clinical trials for next‑generation stem‑cell therapies. Ultimately, scaling the Cincinnati Protocol promises to reduce the societal burden of corneal blindness and create a new growth avenue for the eye‑care market.